Review: Sustainable Clinical Development of CAR-T Cells – Switching From Viral Transduction Towards CRISPR-Cas Gene Editing

T cells modified for expression of Chimeric Antigen Receptors (CARs) were the first gene-modified cell products approved for use in cancer immunotherapy. CAR-T cells engineered with gammaretroviral or lentiviral vectors (RVs/LVs) targeting B-cell lymphomas and leukemias have shown excellent clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Wagner, Dimitrios L., Koehl, Ulrike, Chmielewski, Markus, Scheid, Christoph, Stripecke, Renata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248912/
https://www.ncbi.nlm.nih.gov/pubmed/35784280
http://dx.doi.org/10.3389/fimmu.2022.865424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248912/
https://www.ncbi.nlm.nih.gov/pubmed/35784280
http://dx.doi.org/10.3389/fimmu.2022.865424

Ejemplares similares